Confocal Laser Endomicroscopy for Assessment of Mucosal Healing in Ulcerative Colitis (ENHANCE)

European Georges Pompidou Hospital

Status: Unknown

Conditions: Colitis, Ulcerative

Study type: Observational

Funder types: Other

Identifiers

NCT02676817

2014-A00990-47

Details and patient eligibility

About

The aim of the study is to construct and validate an endomicroscopic score correlated with microscopic inflammation activity in patients with UC.

Probe-based confocal laser endomicroscopy (pCLE) is a new endoscopic imaging modality, which offers the possibility to perform in vivo mucosal microscopic analysis in real time during endoscopy.

Primary Objectives : Development and validation of a UC endomicroscopic score, after correlation between pCLE data and histological data using the Geboes' score as a gold standard during ulcerative colitis.

Secondary Objectives:

• Identify predictive factors for the response to adalimumab.
• Identify predictive factors for recurrence in patients with UC in remission (Mayo score 0 or 1).
• Safety of the pCLE procedure

Full description

Informed consent will be obtained before colonoscopy that includes the known risks and benefits related to the procedure according to the standard protocol of the physician and institution.

A separate informed consent document to participate in the study specific to the approach, technology will be executed.

1. Operator's training before the beginning of the study

   Thirty short pCLE video sequences will be sent to each investigator. Video sequence contains pCLE images of mucosal inflammation in a patient with UC. For each video the correlation with histology is known. The investigator will have to recognize the different pCLE inflammation criteria (Annex 2) and a 90% correct response rate will be required.

2. Endoscopic procedures

MACROSCOPIC examination: colonoscopy

Bowel preparation according to standard protocol was used for colonoscopy. During the colonoscopy, the rectal and colonic mucosal will be analysed with high resolution white light (with or without virtual chromoendoscopy). Before pCLE examination and according to current guidelines, targeted biopsies will be taken in every suspected area of dysplasia for specific histological examination.

MICROSCOPIC examination: pCLE (Cellvizio)

pCLE examination will be done after intravenous injection of fluoresceine (2.5 ml), with the monitoring of cardiovascular and respiratory functions. Three defined area will be analysed: right colon, left colon (40cm from the anus) and the rectum (10cm). Real time analysis and re-reading after the colonoscopy will be done for the video sequences recording during the procedure. A double-blind analysis for each video sequence will be done by two experienced endoscopists.

Rectal and colonic biopsies

For each location (right colon, left colon and rectum), 4 macroscopic area will be indentified (anterior, posterior, left and right), recorded (endoscopic images) and the mucosal inflammation will be scored according to the Mayo's and UCEIS classifications. Then, the probe using for the pCLE procedure will be applied on these 4 different areas and video sequences will be recorded ("optical biopsies"). At the end of the procedure, biopsies will be taken from each area. Each biopsy will have a registration number and the corresponding pCLE video sequence will be specified.

For each location (right colon, left colon, rectum), the final score of inflammation (macroscopic or microscopic) will be define by the higher score recorded in the 4 areas (anterior, posterior, left and righ).

Sensibility to change

For the patients with active UC in group 2 (Mayo' sub-score 2 or 3), a rectosigmoidoscopy should be performed 8 weeks after starting therapy, according to current french guidelines. In order to compare the pCLE examination before and after adalimumab therapy in the group 2, each area will be identified with a submucosal injection of Indian ink.

Enrollment: 100 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age 18 years or older

• Diagnosis of UC established at least for three months, according to the Lennard-Jones' criteria. Two sub-groups will be studied as follows;

  • Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).
  • Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy should be performed 8 weeks after starting therapy, according to current french guidelines. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be treatment-naïve patients.

• Informed consent obtained from the patient

Exclusion criteria

• Allergy to fluorescein
• Pregnancy
• Refusal to participate to the study or inability to consent

Trial design

100 participants in 2 patient groups

Group 1

Description:

Group 1 (n=70) = UC in remission regardless of the medication that allowed remission nor taken by the patient (Mayo' sub-score 0 or 1) and who require colonoscopy regardless of the study according to current guidelines (screening for dysplasia, monitoring during treatment etc).

Group 2

Description:

Group 2 (n=30) = Active UC (Mayo' sub-score 2 or 3) requiring adalimumab and for whom a rectosigmoidoscopy will be performed 8 to 12 weeks after starting therapy, according to current French guidelines and routine practice. Eight weeks after the treatment is the minimum time necessary to evaluate the effects of this treatment according the current practice in France. Then, investigators chose in our study to assess the effects in the group 2 at 8 weeks. All the 30 patients in group 2 will receive adalimumab and they will be anti-TNF naïve patients.